125 results
8-K
EX-10.1
HEPA
Hepion Pharmaceuticals Inc
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors … of contractor invoices in the ordinary course of business approved by a majority of the disinterested directors of the Company, provided that such securities
8-K
EX-4.1
HEPA
Hepion Pharmaceuticals Inc
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable … by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall
8-K
EX-4.2
HEPA
Hepion Pharmaceuticals Inc
16 Feb 24
Entry into a Material Definitive Agreement
9:02am
as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably … by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which
8-K
EX-10.1
s7v 8uemin29
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-4.3
aae498lvziva7k17v
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-4.1
kj1ylhybn6orrur
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-4.2
gfwvc09n7n4 08l
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
424B5
hp6k9w45uuso0v
2 Oct 23
Prospectus supplement for primary offering
4:52pm
424B5
v8b2akbi77k81gou
21 Jul 23
Prospectus supplement for primary offering
4:39pm
8-K
p5db 9gd0
15 Dec 22
Submission of Matters to a Vote of Security Holders
8:25pm
8-K
EX-3.2
vgb6j0 09bkfstlbkv
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-10.1
q96kekedh 7k
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm